Hormone therapy at menopause may pose breast cancer risk
29. 01. 2011 | ecancer.org
Starting hormone therapy at around the time of menopause is associated with a greater risk of breast cancer compared to starting after a longer gap, according to a study published online Jan. 28 in The Journal of the National Cancer Institute .
Image credit: shutterstock.com
In this large, prospectively followed cohort of women, those who started hormone therapy five years or more after menopause had little or no increased risk, regardless of the type of hormone therapy used, how long they used it, and whether they were overweight or obese.
Many studies have established that breast cancer incidence increases in users of hormonal therapy, in particular among women who use an estrogen-progestin combination as opposed to estrogen-alone. Few studies have looked at the timing of hormone therapy as a risk factor, although two previous studies suggested the interval between menopause and initiating hormone therapy may influence breast cancer risk.
- Beral, V., Reeves, G. et al. (2011). Breast cancer risk in relation to the interval between menopause and starting hormone therapy. Journal of the National Cancer Institute DOI: 10.1093/jnci/djq527
- Million Women Study. Cancer Epidemiology Unit, University of Oxford.
- Women’s Health Initiative. Department of Health and Human Services, National Institutes of Health.